The research appears in the October edition of CNS Spectrums: The International Journal of Neuropsychiatric Medicine.

BBC: NEWS | Technology | US shows signs of net addiction

Tsai and his partners will acquire a 60% stake in China Network Systems (CNS) from the private-equity firm MBK Partners.

FORBES: China's Snack King Buys TV Broadcaster

Today CNS is the only company focused on the current and future of the network intrusion prevention solution as well as DDoS defense.

FORBES: DDoS Defense: Preventing business disruption

This article reviews the previous investigations concerning effects of eugenol including its analogs on the CNS and describes perspectives of this highly potential compound.

FORBES: The Lessons Of Failure: What We Can Learn From Bapineuzumab's Blowup

Prior to becoming chairman and CEO of Spectrum, Dr. Shrotriya was the Worldwide Executive Director for CNS (central nervous system) Clinical Research at Bristol Myers-Squibb (BMY), where he worked for 18 years.

FORBES: Straightforward Talk From Spectrum Pharmaceuticals Helps Attract Investors

CB2 receptors, located predominantly in peripheral tissue, exist at very low levels in the CNS. With the development of receptor-specific antagonists, additional information about the roles of the receptors and endogenous cannabinoids in the modulation of pain has been obtained.

FORBES: Billionaire May Try to Legalize Medical Marijuana in Ohio